Editor: Emanuele Marabella
Hey guys! 👋
I can’t believe Palantir Bullets reached its #150 edition, while the stock rose to $180 from $7 when we released Palantir Bullets #1.
That’s a 24x return in 3 years.
As of Palantir Bullets #1, the newsletter had ~750 subscribers. We are now being read by more than 10,000 people every week.
The goal of Palantir Bullets has remained the same: to provide you with quick and digestible information to help you spot asymmetries in the biggest asymmetry in the market in the recent past. The underlying hypothesis has always been that by meticulously following the story, we could outsmart “smart money.”
Obsession dominates credentials.
The obsession that matured in the Palantir community is unprecedented, and over time, the market rewarded it. This precious validation lays the foundation for my next steps as an investor.
Thank you, everybody, for the precious moments we shared. A special thanks to my friend Emanuele Marabella, who encouraged me to pursue this journey and guided me through spectacular deals and insidious controversies.
The most striking part of all of this is probably realizing that Palantir’s story is still in its infancy.
Let’s dominate,
Arny
P.S. Palantir Bullets is free, but if you'd like to support it with a cappuccino, you can do so via the link below.
Last week:
Palantir announced it will release its Q3 results on November 3rd, following the close of US markets.
Palantir partnered with OneMedNet to advance healthcare AI. Palantir’s AIP will provide the infrastructure for OneMedNet’s iRWD™. This near-real-time AI-powered provider network empowers life sciences, medical device, and research organizations with anonymized, regulatory-grade clinical data.
Palantir opened a two-day pop-up shop in Seoul, South Korea, with outstanding participation from retail investors. Almost all the merch was sold after the first day!
Community talk
Tweet of the week
Yours,
Arny
Reach me:
Disclaimer: The views and opinions expressed above are current as of the date of this document and are subject to change without notice. Materials referenced above will be provided for educational purposes only. None of the above will include investment advice, a recommendation or an offer to sell, or a solicitation of an offer to buy, any securities or investment products.